metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Incidental finding of fatty liver in necropsies
Journal Information
Vol. 19. Issue S1.
Abstracts of the 2020 Annual meeting of the Mexican Association of Hepatology (AMH) – XV Congreso Nacional de Hepatología (23-25 de julio)
Pages 1 (September 2020)
Share
Share
Download PDF
More article options
Vol. 19. Issue S1.
Abstracts of the 2020 Annual meeting of the Mexican Association of Hepatology (AMH) – XV Congreso Nacional de Hepatología (23-25 de julio)
Pages 1 (September 2020)
1
Open Access
Incidental finding of fatty liver in necropsies
Visits
724
I.E. Bravo-Espinoza, F. Higuera de la Tijera, G. Arist-Urista, M.A. Durán-Padilla, J.L. Pérez-Hernández, R.Y. López-Pérez, P.L. Pérez-Santos, J.L. Montenegro-Tablada, J. Escobedo-Uribe, A. Servín-Caamaño
Hospital General de México “Dr. Eduardo Liceaga”, Ciudad de México, México
This item has received

Under a Creative Commons license
Article information
Full Text
Download PDF
Statistics
Tables (1)
Table 1. Multivariate predictive models.
Full Text

Background and aim: Non alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (ALD) are the most common emerging causes of chronic liver disease. By knowing the factors involved in their development and screening could improve the prognosis of these patients. To determine prevalence of NAFLD as incidental finding at autopsies performed for all causes of mortality and to analyze the main characteristics of these patients.

Methods: Type and design of the study: Observational, descriptive, transversal study. Last 10 years-death causes reports of Department of Pathology were analyzed (January 2010 – December 2019). Descriptive and analytical statistics: X 2, exact Fisher's test, univariate and multivariate logistic regression models were used.

Results: 4557 autopsies were registered. Fatty liver was found in 6.4% of the cases. 53.3% were women; 51±15 years-old, otherwise 53.6% and 46.4% of the cases were diagnosed with simple steatosis and steatohepatitis with necroinflammatory activity respectively. A 49.8% presented liver fibrosis (F1=13.1%; F2=16.5%; F3=5.2%; F4=15.1%. The etiology through clinical history and histological findings compatible with alcoholic liver injury occurred in 23% of cases, NAFLD 33.7%, mixed type 6.5%, and 36.8% with unidentified etiology. The multivariate analysis showed alcohol intake as the major risk factor for necroinflammation (OR=1.97). History of alcohol intake (OR=2.52;) and presence of necroinflammatory activity (OR=6.53; p<0.0001) were predictive factors of fibrosis F2-F4. (Table 1).

Table 1.

Multivariate predictive models.

A. Multivariate predictive model to evaluate factors associated with the presence of steatohepatitis with hepatic necroinflammatory activity at autopsy.
Variables  p Value  OR  95% CI
      Lower  Higher 
Atherosclerosis  0.008  .405  .208  .789 
Obesity  0.948  1.025  .490  2.144 
Alcohol consumption  0.044  1.974  1.018  3.827 
Diabetes  0.142  .603  .307  1.184 
Arterial hipertension  0.185  1.607  .797  3.238 
Constant  0.351  1.385     
B. Multivariate predictive model to evaluate factors associated with the presence of significant or greater liver fibrosis (F2-F4) at autopsy.
Variables  p Value  OR  IC 95% CI
      Lower  Higher 
Atherosclerosis  0.067  .573  .316  1.041 
Obesity  0.934  1.032  .489  2.178 
Alcohol  0.002  2.529  1.407  4.546 
Diabetes  0.955  1.020  .517  2.011 
Arterial hipertension  0.077  1.811  .938  3.498 
Necroinflammatory activity  <0.0001  6.533  3.720  11.471 
Constant  <0.0001  .176     

Conclusions: Steatosis, steatohepatitis, and fibrosis / cirrhosis were found in a high proportion. Alcohol consumption is significantly associated with liver injury in Mexico.

Conflicts of interest: The authors have no conflicts of interest to declare.

Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2021.100604
No mostrar más